How Boston Scientific's acquisition of Obsidio is shaping its interventional oncology business
In this episode of Boston Scientific Talks, Peter Pattison, President, Interventional Oncology, and Liza Davis, VP of R&D, Interventional Oncology, share insights into the acquisition of Obsidio and the integration of its unique gel embolic material technology into Boston Scientific's portfolio.
The technology, described as a "conformable solid," offers a unique balance between a liquid and solid embolic, providing physicians with precise control and rapid occlusion during interventional oncology procedures. The discussion also covers the successful transition from FDA approval to commercialization, with Obsidio technology already being used in several cases. Looking ahead, Pattison and Davis discuss the potential for further applications of the technology and its integration with Boston Scientific's new coil products.
This episode is sponsored by the Medical Business Unit at TE Connectivity. For more information go to TE.com/medical.
Thank you for listening to the Boston Scientific Talks Podcast.
Subscribe to this podcast on every major podcast platform.
The technology, described as a "conformable solid," offers a unique balance between a liquid and solid embolic, providing physicians with precise control and rapid occlusion during interventional oncology procedures. The discussion also covers the successful transition from FDA approval to commercialization, with Obsidio technology already being used in several cases. Looking ahead, Pattison and Davis discuss the potential for further applications of the technology and its integration with Boston Scientific's new coil products.
This episode is sponsored by the Medical Business Unit at TE Connectivity. For more information go to TE.com/medical.
Thank you for listening to the Boston Scientific Talks Podcast.
Subscribe to this podcast on every major podcast platform.
Activity